Dr. Sobolov is an experienced biopharmaceutical executive and a proven R&D leader with a passion for delivering transformative drugs for patients. She has leadership experience across all aspects of the drug discovery-development lifecycle in companies ranging from large caps to smaller public and private biotech companies (Pfizer, Novartis, Alexion, Caelum Biosciences, and Fortress Biotech).

Her experience spans a broad range of therapeutic areas: CNS, oncology, antivirals, and rare diseases, from target identification through global regulatory submission. She has delivered programs across a wide range for drug modalities including small molecules, biologics, mRNA therapeutics, along with cell and gene therapies. Beyond leading R&D, manufacturing, quality, and project management, she has P&L management experience and has supported successful financings and business development initiatives. Prior to joining RIGImmune as President, Susan was COO at Caelum Biosciences which completed a successful acquisition by AstraZeneca in October 2021. She currently is an entrepreneur in residence with the UCONN Technology incubator program, serves on several scientific advisory boards, and co-founded the Women in Bio Connecticut chapter in 2021.

Prior to Caelum, Dr. Sobolov was Vice President of Strategy, Portfolio and Program Management at Fortress Biotech where she worked across numerous subsidiary companies, building their programs and companies. Dr. Sobolov completed a post-doctoral fellowship at Harvard Medical School in enzymology and molecular biology after obtaining her Ph.D. in synthetic organic chemistry from Yale.